GMABGenmab A/S ADS

ADRCNasdaq (XNAS)·USD

Identity

Security key: 16088
Ticker: GMAB
Type: ADRC — American Depository Receipt Common
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2010-10-05
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: GMAB

Detail

Enriched 2026-08-14 20:47

Market cap: $19,311,436,750.6
Shares outstanding (class): 623,532,520
Shares outstanding (weighted): 614,622,430
SIC: —
Employees: 3,088
Location: —
Homepage: https://www.genmab.com
Description: Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Market cap and share counts drift.

Funds holding this security

23 funds · 23 positions · $193.26M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
iShares Biotechnology ETF iShares Trust	IBB	$95.38M	1.17%	3,555,098 NS	FIGI
First Trust NYSE Arca Biotechnology Index Fund First Trust Exchange-Traded Fund	FBT	$63.16M	2.78%	2,354,019 NS	FIGI
Mercer Non-US Core Equity Fund Mercer Funds	—	$4.82M	0.11%	179,676 NS	FIGI
LVIP AllianceBernstein Large Cap Growth Fund LINCOLN VARIABLE INSURANCE PRODUCTS TRUST	—	$4.40M	0.30%	163,812 NS	FIGI
Fidelity Enhanced International ETF Fidelity Covington Trust	FENI	$4.21M	0.05%	156,871 NS	FIGI
Timothy Plan International Fund Timothy Plan	—	$3.68M	1.84%	137,000 NS	FIGI
AB Large Cap Growth Portfolio AB VARIABLE PRODUCTS SERIES FUND, INC.	—	$2.82M	0.31%	105,277 NS	FIGI
SIMT Large Cap Fund SEI INSTITUTIONAL MANAGED TRUST	—	$2.22M	0.16%	82,643 NS	FIGI
LVIP Blended Large Cap Growth Managed Volatilit… LINCOLN VARIABLE INSURANCE PRODUCTS TRUST	—	$2.13M	0.14%	79,399 NS	FIGI
First Trust Nasdaq BuyWrite Income ETF First Trust Exchange-Traded Fund VI	FTQI	$1.97M	0.25%	73,468 NS	FIGI
SIMT Large Cap Value Fund SEI INSTITUTIONAL MANAGED TRUST	—	$1.62M	0.12%	60,494 NS	FIGI
SIMT Tax-Managed Large Cap Fund SEI INSTITUTIONAL MANAGED TRUST	—	$1.36M	0.03%	50,811 NS	FIGI
Quantified Global Fund Advisors Preferred Trust	—	$1.36M	4.89%	50,720 NS	FIGI
AdvisorShares Dorsey Wright ADR ETF AdvisorShares Trust	AADR	$827.8K	1.83%	30,853 NS	FIGI
Virtus Small-Cap Fund Virtus Investment Trust	—	$737.7K	0.69%	27,495 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERGMAB
FIGI_COMPOSITEBBG004MPKM64
FIGI_SHARE_CLASSBBG004MPKMY3
CIK0001434265
ISINUS3723032062
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Genmab is a biotech company developing antibody therapeutics, so it falls under healthcare biotechnology.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.